[et_pb_section fb_built=”1″ fullwidth=”on” admin_label=”Sezione” _builder_version=”4.16″ background_enable_color=”off” height=”400px” custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px||0px|false|false” bottom_divider_style=”slant2″ bottom_divider_color=”#ffffff” global_colors_info=”{}”][et_pb_fullwidth_post_title title=”off” meta=”off” featured_placement=”background” _builder_version=”4.16″ title_text_align=”left” background_color=”#e02b20″ custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false” global_colors_info=”{}”][\/et_pb_fullwidth_post_title][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ custom_padding=”100px|0px|0px|0px|false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.27.6″ text_font_size=”16px” header_text_align=”left” header_2_text_align=”left” background_size=”initial” background_position=”top_left” background_repeat=”repeat” header_text_align_tablet=”” header_text_align_phone=”” header_text_align_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n
Early monitoring of patients treated with Romosozumab<\/b><\/p>\n
The study “<\/b>Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology<\/i><\/b>“, <\/b>just published on Aging Clinical and Experimental Research<\/i> (ACER) journal By Semeraro and colleagues,<\/b> assessed for the first time the effectiveness of the Radiofrequency Echographic Multi Spectrometry (REMS) for very short-term monitoring of Romosozumab (RMZ) in postmenopausal women after only 6 months of treatment.\u00a0<\/span><\/p>\n As we already know, Romosozumab\/AMG785 (Evenity\u00ae, Amgen and UCB pharma) is a sclerostin-neutralizing antibody that rapidly increases BMD, but very short-term monitoring in clinical routine is limited by specific issues of available ionizing techniques. \u00a0<\/span><\/p>\n Seventy-four postmenopausal women who underwent non-ionizing REMS scans of the proximal femur at baseline and after 6 months of RMZ treatment were included in this study. Exploratory analyses were also performed in treatment-na\u00efve patients and in women with \u22652 previous fragility fractures.<\/p>\n After six months of RMZ, BMD significantly increased at both Total Hip (+3.7%; p < 0.01) and Femoral Neck (+4.1%; \u2264 0.01). In treatment-na\u00efve patients, BMD gains were larger (Total Hip +4.7%; Femoral Neck +4.6%), as also in women with \u22652 prior fractures, where Total Hip BMD increased by 4.1% and Femoral Neck BMD by 4.8% confirming the literature-available DXA-based results. In untreated controls, no significant changes were observed at either Total Hip (-0.8%; p > 0.05) or Femoral Neck (-0.6%; p > 0.05).\u00a0<\/span><\/p>\n The findings support the feasibility of REMS for very short-term follow-up in real-world settings. The possibility of performing frequent radiation-free assessments may facilitate closer follow-up in clinical practice and enable a more timely evaluation of treatment response. In addition, because anthropometric parameters did not change significantly over the considered 6 months, the reported REMS BMD variations are not confused by anthropometric changes and are consistent with actual very short-term skeletal effects of therapy.<\/p>\n [\/et_pb_text][et_pb_button button_url=”https:\/\/www.echolightmedical.com\/wp-content\/uploads\/2026\/04\/Semeraro-et-al.-2026.pdf” url_new_window=”on” button_text=”Download .pdf” button_alignment=”left” _builder_version=”4.27.6″ global_colors_info=”{}”][\/et_pb_button][et_pb_divider color=”#e3e3e3″ divider_position=”bottom” _builder_version=”4.16″ module_alignment=”center” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ background_enable_color=”off” use_background_color_gradient=”on” background_color_gradient_stops=”#fff 0%|#f3f3f3 100%” background_color_gradient_start=”#fff” background_color_gradient_end=”#f3f3f3″ custom_margin=”||||false|false” custom_padding=”||250px||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_blog fullwidth=”off” posts_number=”3″ include_categories=”10″ show_more=”on” show_author=”off” show_categories=”off” show_pagination=”off” disabled_on=”off|off|off” _builder_version=”4.16″ meta_text_color=”#b3b3b3″ scroll_blur_enable=”on” scroll_blur=”12|19|29|40|10px|2px|0px” motion_trigger_start=”top” border_width_all=”0px” box_shadow_style=”preset3″ global_colors_info=”{}”][\/et_pb_blog][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Form” module_id=”form” _builder_version=”4.14.8″ _module_preset=”default” background_color=”#f8f8f8″ module_alignment=”center” custom_margin=”-1%||||false|false” custom_padding=”||7%||false|false” global_module=”9688″ saved_tabs=”all” collapsed=”off” global_colors_info=”{}”][et_pb_row module_id=”form_en” module_class=”riga_form” _builder_version=”4.16″ _module_preset=”default” width=”100%” max_width=”100%” custom_padding=”6.3%|18.7%||18.7%|false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n\n <\/p> <\/ul><\/div>\n